coadministered cagrilintide and semaglutide in adults with overweight or obesity | NEJM REDEFINE 1 Trial Finds Cagrilintide–Semaglutide

Compounded alternatives as a cost lever Between 2022 and 2024 the FDA listed semaglutide on its drug shortage list, opening a pathway for licensed 503A compounding pharmacies to compound semaglutide formulations

Lawsuits filed allege that drug companies ignored significant evidence of these risks and continued to market these drugs as safe weight loss medications

Variants in FTO (the fat-mass and obesity-associated gene), MC4R (a melanocortin receptor central to satiety and energy balance), GLP1R (the receptor every GLP-1 compound targets), and TCF7L2 (a transcription factor linked to glucose homeostasis) describe the baseline terrain a GLP-1 protocol acts on

NET CONTENT

This demonstration allows states a partial waiver of the inmate exclusion policy, which prohibits Medicaid from paying for services provided during incarceration (except for inpatient services)